Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of Switching from IV to SC Abatacept in RA
NCT00663702Phase 3Completed
- Sponsor
- Bristol Myers Squibb
- Start
- May 2008
- Primary completion
- Dec 2009
- Modality
- Fc-Fusion Proteins
- Countries
- 3
01
Overview
A Phase 3 trial of abatacept in rheumatoid arthritis (RA), sponsored by Bristol Myers Squibb. Started May 2008; status: completed.
02
Drugs
abatacept
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT00663702.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00663702.